

Amendment to the Claims

This listing of claims will replace all prior versions and listings of claims in this application:

Listing of Claims:

1. (Currently amended) A method of treating Parkinson's disease in a human in need of such treatment comprising: the administration to a human in need of such treatment of an antiparkinson therapeutic amount of an antiparkinson agent selected from the group consisting of an anticholinergic agent; a dopaminergic agent; a monoamine oxidase agent; and amantadine, and an anti-inflammatory effective amount of a selective COX-2 inhibitor.
2. (Cancelled)
3. (Cancelled)
4. to 6. (Cancelled)
7. (Currently amended) A method according to claim [[2]] 1, wherein the dopaminergic agent comprises a dopamine precursor or a dopamine receptor agonist.
8. (Currently amended) A method according to claim [[2]] 1, wherein the dopaminergic agent comprises levodopa, bromocriptine, pergolide, pramipexole, cabergoline or ropinorole.
9. (Withdrawn) A method according to claim 2 wherein the monoamine oxidase agent comprises selegiline.
10. (Currently amended) A method according to claim [[2]] 1, further comprising a second an antiparkinson agent.
11. (Currently amended) A method for the treating Hoehn & Yahr Stage I-III Parkinson's disease, which method comprises administration to a patient in need of such treatment of an amount of a selective COX-2 inhibitor and an amount of an anti-parkinsonism agent selected from the group consisting of an anticholinergic agent; a dopaminergic agent; a monoamine oxidase agent; and amantadine, such that together they provide effective treatment.

12. (Currently amended) A method of relieving the symptoms of Parkinson's disease, which method comprises administration to a patient in need of such treatment of an amount of a selective COX-2 inhibitor and an amount of an antiparkinson agent selected from the group consisting of an anticholinergic agent; a dopaminergic agent; a monoamine oxidase agent; and amantadine, such that together they provide effective relief.
13. (Currently amended) A method of treating Parkinson's disease, which method comprises administration to a patient in need of such treatment of an amount of a selective COX-2 inhibitor and an amount of an anti-parkinsonism agent selected from the group consisting of an anticholinergic agent; a dopaminergic agent; a monoamine oxidase agent; and amantadine, such that together the agents provide greater relief than that obtained by administration of the antiparkinson agent alone.
14. (Currently amended) A method for ameliorating the progress of Parkinson's disease, which method comprises administration to a patient in need of such treatment of a therapeutically effective amount of a selective COX-2 inhibitor and an amount of an antiparkinson agent selected from the group consisting of an anticholinergic agent; a dopaminergic agent; a monoamine oxidase agent; and amantadine, such that together they provide effective amelioration.
15. (Currently amended) A method for slowing the progress of Parkinson's disease, which method comprises administration to a patient in need of such treatment of a therapeutically effective amount of a selective COX-2 inhibitor and an amount of an antiparkinson agent selected from the group consisting of an anticholinergic agent; a dopaminergic agent; a monoamine oxidase agent; and amantadine, such that together they are effective in slowing the progress of the disease.
16. - 19. (Cancelled)
20. (Previously presented) A method according to Claim 1, wherein the selective COX-2 inhibitor is rofecoxib (VIOXX®).
21. (Previously presented) A method of treating Parkinson's disease in a human in need of such treatment according to claim 1 comprising: the administration to a human in need of such

U.S.S.N.: 10/539,872
Case No.: 21309YP
Page No: 4
Date: June 12, 2009

treatment of an antiparkinson therapeutic amount of pergolide, an antiparkinson therapeutic amount of selegiline and an anti-inflammatory effective amount of rofecoxib (VIOXX®).